Navigation Links
Bioheart, Inc. Announces Financial Results for First Quarter 2008
Date:5/15/2008

SUNRISE, Fla., May 15 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today announced financial results for the quarter ended March 31, 2008.

Financial Highlights

-- On February 19, 2008, the Company completed its initial public offering

(IPO) of common stock for gross proceeds of approximately $5.8 million.

The net cash proceeds from the IPO are expected to be utilized to

commence full-scale enrollment in a Phase II/III MARVEL Clinical Trial

of MyoCell(R) in the U.S. and Europe.

Clinical Highlights

-- On January 18, 2008, the final 12-month results of the MYOHEART Trial,

a Phase I dose-escalation study of MyoCell in the United States, the

Company's lead product candidate, were presented at the Fourth Annual

International Conference on Cell Therapy for Cardiovascular Diseases

(NY). The results, presented by Warren Sherman, MD, Principal

Investigator and Director, Cell-based Endovascular Therapies, Columbia

University Medical Center, NY, suggested trends in improved quality of

life measurements sustained out to 12 months following treatment,

without unexpected rates of serious adverse events related to the

therapy given its patient population.

-- On April 1, 2008, the final six-month results of the Phase II SEISMIC

Trial of MyoCell in Europe, was presented during the clinical trial

sessions at the American College of Cardiology. These results suggested

that MyoCell is a safe and potentially effective alternative treatment

to standard medical therapy alone for improving heart function among

patients with previously implanted cardiac devices who are experiencing

congestive hea
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Clinovo Staffing Solutions will ... held in Orlando, FL on May 17-20th, 2015. ... Leslie Kolman, Manager of Staffing Solutions, will present Clinovo’s ... Booth #17. , “We are excited to be ... Says Trisha Heredia, Senior Director of Staffing Solutions at ...
(Date:4/29/2015)... Maryland, USA (PRWEB) April 29, 2015 ... optical sensing, and imaging on the East Coast, reaffirmed ... program managers, researchers, applications developers, and industry suppliers to ... and imaging for multiple applications. , The event included ... and commercial and scientific sensing and imaging -- and ...
(Date:4/29/2015)... EAST RUTHERFORD, N.J. , April 29, 2015 ... 2015 financial results will be released on Friday, May 1, ... The Company will host a conference ... Conference Call When: , Friday, ... Dial-in: , 1-888-468-2440 for U.S.1-719-325-2454 for International ...
(Date:4/29/2015)... Gene therapy can clip out genetic material linked to ... human cardiac cells, according to a study led by researchers ... at Mount Sinai. The study is published in the April ... small random, changes in the genetic code making up genes, ... patients with heart failure,” says Roger J. Hajjar, MD, Director ...
Breaking Biology Technology:Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4Gene Therapy Clips Out Heart Failure Causing Gene Mutations 2Gene Therapy Clips Out Heart Failure Causing Gene Mutations 3Gene Therapy Clips Out Heart Failure Causing Gene Mutations 4
... April 1 Nutrition 21, Inc. (Nasdaq: ... that help consumers manage blood sugar levels, improve cardiovascular ... today that on March 31, 2009 it redeemed all ... required by the terms of these shares. The Company ...
... and Saint Joseph,s Hospital Team UpATLANTA, April 1 ... have joined together to begin the first regional research ... pancreatic cancer. Tissue and serum samples from patients ... in genetic and cellular features between normal and tumor ...
... to prior yearROCHESTER, N.Y., April 1 VirtualScopics, Inc. ... quantitative imaging for clinical trials, today announced that its ... its active and awarded projects and commonly referred to ... million which compares to $13.7 million at the same ...
Cached Biology Technology:Nutrition 21 Redeems Series I Convertible Preferred Shares 2Nutrition 21 Redeems Series I Convertible Preferred Shares 3Groundbreaking Research Begins for Pancreatic and Lung Cancers 2Groundbreaking Research Begins for Pancreatic and Lung Cancers 3VirtualScopics' Project Balance Exceeds a Record $31 Million 2VirtualScopics' Project Balance Exceeds a Record $31 Million 3
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... 23, 2015 SoundView Technology Group issues a new ... NXTD ) Wocket smart wallet. SoundView was one of the selected ... experience with the Wocket in multiple scenarios and outlets. ... and other retailers, making both debit and credit card payments.  ... says, "If the company meets their plans in 2015, it ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Thirty to fifty percent of the global conversion of nutrients ... of the National Academy of Science of the United States ... state that this conversion is not carried out by denitrifying ... Nitrogen compounds act as fertilizers and are the ecological basis ...
... with variant Creutzfeldt-Jakob (vCJD) prions may no longer be ... a transfusion. Pall Corporation (NYSE: PLL) announced today the ... Prion Reduction Filter System. It is the first and ... the causative agent of vCJD from red cells, the ...
... only three months after deciding to create an ... trial registry and results database using an independent ... trials can be accessed by anyone, anywhere, with ... give patients and healthcare providers ready access to ...
Cached Biology News:Anammox bacteria produce nitrogen gas in oceans' snackbar 2Anammox bacteria produce nitrogen gas in oceans' snackbar 3First technology to remove prions that cause vCJD from blood launched 2First technology to remove prions that cause vCJD from blood launched 3First technology to remove prions that cause vCJD from blood launched 4Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3
... The antiserum has been tested on tissue ... staining pattern obtained with AB1773 corresponds to ... with probes to GLYT2 mRNA and to ... Preabsorption of the antiserum with the immunogen ...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide ... LIGHT. PACKAGED UNDER INERT GAS. A potent ... dose-dependent manner (K i = 1.7 ... Soluble in EtOH or DMSO. Unstable in ...
... Reacts with an early protein. ... 3 hours post-infection exhibiting an ... peak intensity between 6-24 hours. ... intense coarsely granular staining. ...
Biology Products: